BACKGROUND Patients with severe aortic stenosis (AS) who were deemed too high risk or inoperable for conventional
S ymptomatic aortic stenosis (AS) has a dismal prognosis. Despite this, up to two-thirds of patients with severe AS do not undergo surgical aortic valve replacement (AVR) due to their comorbidities (1) (2) (3) (4) (5) (6) . Thus, after some small, but promising feasibility studies and trials, the applicability of transcatheter aortic valve replacement (TAVR) for these high-risk patients has evolved rapidly (6) (7) (8) (9) (10) . The 2-armed randomized PARTNER (Placement of Aortic Transcatheter Valves) trial was designed to test the procedure for safety and effectiveness. Patients in the PARTNER-A arm were considered high risk for surgery; patients in the PARTNER-B arm were considered inoperable.
This detailed analysis reports on deaths among patients in both trial arms, including those that occurred between randomization and the procedure, focusing on when and how the deaths occurred (11) (12) (13) (14) .
METHODS PATIENTS.
A total of 3,105 patients were presented to a Web-based review panel for potential inclusion in the PARTNER trial. All patients were required to have a Society of Thoracic Surgeons (STS) score of >10%, unless comorbidities that were not part of the score assessment were present (e.g., radiation heart disease, cirrhosis, or porcelain calcification of the aortic arch without a distal landing site for a replacement graft). Patients were required to have an aortic valve area <0.8 cm 2 and either a mean transaortic gradient of >40 mm Hg or a transvalvar velocity of >4.0 m/s (11) (12) (13) (14) . High-risk patients were required to have a >15% probability of 30-day mortality, as deemed by the surgeon, irrespective of the STS score.
Of the reviewed patients, 699 were considered
high risk for open surgery (PARTNER-A), and 358
were considered inoperable (PARTNER-B). Before randomization, a determination was made as to whether each patient was suitable for the transfemoral (TF) or the transapical (TA) approach. Of PARTNER-A patients, 348 were randomized to TAVR-244 to a TF approach (TF-TAVR) and 104 to a TA approach (TA-TAVR) (depending on vascular access)-and 351 were randomized to AVR (12) .
The inoperable PARTNER-B subset was defined as those patients who were deemed by 2 cardiac surgeons as having a >50%
probability of death or irreversible severe morbidity after AVR (11) . Of PARTNER-B patients, 179 were randomized to TF-TAVR and 179 to standard therapy (medical management with or without balloon aortic valvotomy).
Baseline patient characteristics were similar among subsets of both PARTNER-A and PARTNER-B arms (11) (12) (13) (14) . The trial was approved by the U.S. Food and Drug Administration and the institutional review board at each participating center. Additional trial details are described in earlier publications (11) (12) (13) (14) .
All patients who underwent TAVR received the Edwards Sapien valve (Edwards Lifesciences, Irvine, California).
ENDPOINTS. The primary endpoint was all-cause mortality from time of randomization (intentto-treat). The Online Appendix provides analyses of as-treated mortality in PARTNER-A. Secondary endpoints were categories and subcategories of deaths.
A l l -c a u s e m o r t a l i t y . Median follow-up was 2 years for PARTNER-A patients, and 10% of the survivors were followed for more than 3 years; 1,154 patientyears of follow-up were available for analyses. Median follow-up was 1.3 years for PARTNER-B patients, and 10% of the survivors were followed for more than 3.2 years; 541 patient-years of follow-up were available for analyses. All time-related depictions were truncated at 2.5 years. Mortality information was current as of April 25, 2012. (A) Instantaneous risk of death among patients randomized to standard therapy (red) or TF-TAVR (blue). Format is as in Figure 1A. (B) Survival stratified by randomized groups. Format is as in Figure 1B . (C) Estimated lifetime gained by TF-TAVR over standard therapy. This represents the integrated difference between TF-TAVR and standard therapy survival curves in Figure 2B . Dashed lines form a 90% confidence band. Abbreviations as in Figure 1 .
C a t e g o r i z a t i o n o f d e a t h s .
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Causes of Death in the PARTNER Trial
T h e P A R T N E R -B T r i a l . At the date of last followup, 237 PARTNER-B patients had died, 2 between randomization and TF-TAVR (1.1%). For patients randomized to TF-TAVR, the pattern of instantaneous risk of death paralleled that of TF-TAVR for PARTNER-A patients, although at a somewhat higher level ( Fig. 2A) . Those randomized to standard therapy, however, exhibited an early peakpossibly related to balloon aortic valvotomy-that was prolonged beyond 6 months and merged with a constant hazard that was considerably higher than that after TF-TAVR, and higher than that expected for the general population. Thus, survival diverged between the 2 trial arms within 30 to 60 days, and the gap widened thereafter (Fig. 2B) . Table 1 ).
Instantaneous risk of cardiovascular death peaked earlier after randomization to TF-TAVR than to AVR (Fig. 3A) . Instantaneous risk of noncardiovascular death also peaked after randomization, but the peak was higher and earlier in the AVR group than in either the TA-TAVR or TF-TAVR groups (Fig. 3B , Online
Figs. 5A to 5C). Of deaths between randomization and procedure, 2 in the TF-TAVR group were cardiovascular (arrhythmia and heart failure), and 1 death in the TA-TAVR group was uncategorizable (Online Appendix). Of the 17 deaths in the AVR group, 8
were cardiovascular (2 arrhythmia, 4 heart failure, 2 sudden), 5 were noncardiovascular (2 infection, 1 renal failure, 1 encephalopathy, 1 necrotic bowel), and 4
were uncategorizable.
T h e P A R T N E R -B T r i a l . Among PARTNER-B patients, death was categorized as cardiovascular in 107 patients, noncardiovascular in 53, and uncategorizable in 77 ( Table 1, Online Table 2 ). Instantaneous risk of cardiovascular death during standard therapy remained elevated well above risk after randomization to TF-TAVR (Fig. 4A, Online Figs. 6A and 6B ).
Risk of cardiovascular death peaked early after TF-TAVR, fell to lower levels within approximately 6 months, and gradually rose after approximately 1 year, similar to that observed in PARTNER-A patients (Online Fig, 7A ). Although risk of noncardiovascular death peaked after randomization to TF-TAVR, the general level of risk was similar to that of standard therapy ( Fig. 4B) and noncardiovascular death in PARTNER-A patients (Online Fig. 7B ). One death between randomization and intended TF-TAVR was due to heart failure, and 1 was uncategorizable.
SUBCATEGORIES OF CARDIOVASCULAR DEATH.
The 2 most common subcategories of cardiovascular death among PARTNER patients were heart failure and sudden death (Tables 1 and 2) . Risk of death from heart failure after TAVR or AVR peaked early after the procedure (Fig. 5A) , unlike that for sudden death (Fig. 5B) . In PARTNER-B patients, the risk was more protracted, but risk of death from heart failure remained elevated during standard therapy (Fig. 6A) . Risk of sudden death occurred at a low level among patients randomized to an aortic valve intervention in both PARTNER-A and PARTNER-B.
However, risk was considerably higher and remained elevated in patients randomized to standard therapy (Fig. 6B) .
SUBCATEGORIES OF NONCARDIOVASCULAR DEATH.
The most common subcategories of noncardiovascular death among PARTNER patients were infection, respiratory complications, and malignancies (Tables 1 and 2 ). There were 24 noncardiovascular deaths in the "other" category: 8 from neurological events, 2 from multisystem organ failure, 5 from liver failure, 7 from gastrointestinal complications, and 2 from uncertain noncardiovascular causes ( Table 3) .
Close examination of clinical source documents from PARTNER-B patients whose deaths could not be categorized showed that they were later deaths that occurred in nursing homes or hospices, were associated with old age, frailty, or failure to thrive, and could not be further characterized. Tables 1 and 2 ).
There were no deaths from hemolysis; only 1 patient experienced documented hemolysis, and that was after AVR.
DISCUSSION OVERALL RISK OF DEATH. T e m p o r a l P a t t e r n o f R i s k . The instantaneous risk of death (hazard function) following intervention is initially high, then falls
to a low level before gradually rising (Central Illustration). This "bathtub-shaped" risk following open cardiac surgical procedures has been observed for several decades (15, (18) (19) (20) . Clinical management of patients after surgery mirrors this pattern of risk: intensive care, step-down unit, regular nursing floor, and discharge to a nearby hotel or home.
Nevertheless, the period of higher risk extends well beyond initial hospitalization, as was found in the present study. This corresponds with elevated risk of hospital readmissions soon after hospital discharge.
However, an important novel finding is that early risk after randomization to TF-TAVR in PARTNER-A and -B was substantially lower than after TA-TAVR or AVR. Thus, an advantage of a percutaneous approach is a reduction of peri-procedural risk, particularly noncardiovascular risk.
The shape of the elevated early hazard phase is not typical of that previously found for surgical intervention, in that it peaks for the surgical cohorts.
Generally, risk is highest immediately after a procedure, then falls steeply. The explanation lies in the nature of this intent-to-treat analysis. The interval between randomization and the procedure has a lengthy "right tail" of up to several weeks or months.
The peaking early hazard phase is a result, as demonstrated when an "as treated" analysis of instantaneous risk is performed (Online Fig. 12A ): the peak disappears, and risk starts high immediately after the procedure. Thereafter, the contour of the Abbreviations as in Figure 1 .
Causes of Death in the PARTNER Trial hazard function is similar to the depiction shown in Figure 1A .
In addition, the magnitude of early risk after randomization to AVR reflects 4.8% mortality in this group before surgery. This contrasts with 0.9% mortality between randomization and TAVR in the combined PARTNER trial arms. In observational surgical studies that nearly always commence at operation, deaths before planned surgery are rarely reported. This is in contrast to inception cohort studies, such as randomized trials and some studies on managing congenital heart disease (21). Bavaria et al. (22) reported a 12% mortality between referral for TAVR and procedure in their program, and others reported even higher mortality for patients screened for possible valve replacement (23, 24) . R e l a t i o n t o r i s k i n t h e g e n e r a l p o p u l a t i o n . After early high risk falls to its lowest level, risk of death is commensurate with that of the age-, sex-, and race-matched general population. Thereafter, it gradually begins to rise above that expected in the general population. In these elderly patients, this rise is also accelerated beyond that expected in the general population. Patient demographic characteristics, comorbidities, and new health problems (e.g., strokes) likely contribute to the post-recovery increase in risk. These contrast sharply with the rates observed after surgical reports of AVR, for which instantaneous risk of death is progressively less than that of the general population as patient age increases (20) , which is probably due to the selection of lower risk patients for conventional heart surgery.
V a l u e o f i n t e r v e n t i o n . Survival results of the PARTNER-B randomized trial reported previously (11) (12) (13) (14) , and evaluated further in this study, demon- It was beyond the scope of this study to translate added lifetime from TAVR over standard therapy to quality-adjusted life years (25) , a necessary step in assessing cost effectiveness of treatments. In addition, we did not perform a multivariable analysis of death to identify risk factors for both early and late deaths in the various patient subsets. Thus, we did not address the possibility that some patients benefitted more than others from intervention.
These are subjects of forthcoming investigations. Values are n (%).
Abbreviations as in Table 1 .
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